Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.50 |
| ▸ | HK1 | P19367 | 1/20 | 0.46 |
| ▸ | HK2 | P52789 | 1/20 | 0.46 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78953 | 1.00 | CYP1A2 (0.50) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL6250991 | 1.00 | CYP1A2 (0.50) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL384784 | 1.00 | CYP1A2 (0.50) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL60404 | 1.00 | CYP1A2 (0.50) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL149792 | 1.00 | CYP1A2 (0.50) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL3630100 | 1.00 | CYP1A2 (0.50) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL148556 | 1.00 | CYP1A2 (0.50) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL1314276 | 1.00 | CYP1A2 (0.50) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| SCHEMBL869268 | 1.00 | CYP1A2 (0.50) | CYP1A2NFKB1THPOALDH1A1PMP22 | |
| D-Galactose SCHEMBL16275082 | 0.97 | CYP1A2 (0.48) | CYP1A2NFKB1THPOALDH1A1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2718459-A2 | COMPETITION-BASED DETECTION ASSAYS | Shire Human Genetic Therapies, Inc. (US) | 2014-04-16 | — | — | EP | claimed |
| WO-2012170870-A2 | COMPETITION BASED-DETECTION ASSAYS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2012-12-13 | — | — | WO | claimed |
| US-8236520-B2 | Recombinant beta-galactosidase derived from Streptococcus pneumoniae | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-08-07 | — | — | US | claimed |
| US-20110287463-A1 | RECOMBINANT BETA-GALACTOSIDASE DERIVED FROM STREPTOCOCCUS PNEUMONIAE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2011-11-24 | — | — | US | claimed |
| EP-0122023-A1 | Microorganisms detection methods and the separation of agglutinated microorganisms, and a kit for use therein | E-Y LABORATORIES, INC. (US) | 1984-10-17 | — | — | EP | claimed |
| CN-104090095-B | Molecular conjugate | VENTANA MEDICAL SYSTEMS, INC. (US) | 2016-06-01 | — | — | CN | disclosed |
| US-9023814-B2 | Glycomimetic compounds as anti-infectious against pathogens lectins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2015-05-05 | — | — | US | disclosed |
| EP-2798075-A1 | METHOD OF DETECTING A SALMONELLA MICROORGANISM | 3M Innovative Properties Company (US) | 2014-11-05 | — | — | EP | disclosed |
| WO-2014154806-A1 | PROCESS FOR PREPARING PARTIALLY DEGALACTOSYLATED XYLOGLUCAN AND ITS USE FOR OILFIELD APPLICATIONS | BASF SE (DE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014154814-A1 | METHOD FOR BLOCKING PERMEABLE ZONES IN OIL AND NATURAL GAS BEARING SUBTERRANEAN FORMATIONS BY IN-SITU XYLOGLUCAN DEGALACTOSYLATION | BASF SE (DE) | 2014-10-02 | — | — | WO | disclosed |
| EP-2649085-B1 | GLYCOMIMETIC COMPOUNDS AS ANTI-INFECTIOUS AGAINST PATHOGENS LECTINS | CENTRE NAT RECH SCIENT (FR) | 2014-08-20 | — | — | EP | disclosed |
| EP-2723885-A2 | METHOD FOR CLASSIFYING THE PRESENCE OR ABSENCE OF A MICROORGANISM IN A BIOLOGICAL MEDIUM | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2014-04-30 | — | — | EP | disclosed |
| US-5194425-A | MHC-MEDIATED TOXIC CONJUGATES USEFUL IN AMELIORATING AUTOIMMUNITY | ANERGEN, INC. (US) | 1993-03-16 | — | — | US | disclosed |
| EP-0423201-A4 | MHC-MEDIATED TOXIC CONJUGATES USEFUL IN AMELIORATING AUTOIMMUNITY | — | 1992-10-14 | — | — | EP | disclosed |
| US-5130297-A | Conjugates useful in ameliorating autoimmunity MHC-II-peptide | ANERGEN, INC. (US) | 1992-07-14 | — | — | US | disclosed |
| WO-1991019000-A1 | A MONOCLONAL ANTIBODY AGAINST THE GAG PROTEIN PRECURSOR p55 OF HUMAN IMMUNODEFICIENCY VIRUS | GRUPPO LEPETIT S.P.A. (IT) | 1991-12-12 | — | — | WO | disclosed |
| EP-0423201-A1 | MHC-MEDIATED TOXIC CONJUGATES USEFUL IN AMELIORATING AUTOIMMUNITY. | BIOSPAN CORP (US) | 1991-04-24 | — | — | EP | disclosed |
| WO-1989012459-A1 | MHC-MEDIATED TOXIC CONJUGATES USEFUL IN AMELIORATING AUTOIMMUNITY | BIOSPAN CORPORATION (US) | 1989-12-28 | — | — | WO | disclosed |
| EP-0304291-A1 | Dosage form using an antagonist to gamma interferon to control MHC-associated autoimmune disease | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 1989-02-22 | — | — | EP | disclosed |
| EP-0122023-A1 | Microorganisms detection methods and the separation of agglutinated microorganisms, and a kit for use therein | E-Y LABORATORIES, INC. (US) | 1984-10-17 | — | — | EP | disclosed |